Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
06-2014 | 03-2014 | 12-2013 | 09-2013 | 06-2013 | |
Cash Flows From Operating Activities | |||||
Net Income | 2,472,478 | 1,186,335 | 4,485,271 | 3,397,666 | 2,227,843 |
Depreciation Amortization | N/A | N/A | 498,502 | N/A | N/A |
Accounts receivable | N/A | N/A | -225,831 | N/A | N/A |
Accounts payable and accrued liabilities | N/A | N/A | 41,497 | N/A | N/A |
Other Working Capital | -549,562 | -218,236 | 105,613 | -98,390 | -367,219 |
Other Operating Activity | 318,341 | -220,624 | -284,783 | 353,956 | 654,022 |
Operating Cash Flow | $2,241,257 | $747,475 | $4,620,270 | $3,653,232 | $2,514,646 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 407,852 | 222,828 | 144,439 | 88,445 | 262,625 |
PPE Investments | -274,781 | -127,304 | -571,167 | -438,317 | -273,312 |
Sale Of Investment | N/A | N/A | 5,165 | N/A | N/A |
Purchase Sale Intangibles | -32,533 | -19,105 | -72,309 | -50,083 | -33,638 |
Other Investing Activity | -32,533 | -19,105 | -72,309 | -50,083 | -33,638 |
Investing Cash Flow | $100,539 | $76,419 | $-493,871 | $-399,955 | $-44,326 |
Cash Flows From Financing Activities | |||||
Common Stock Repurchased | -1,257,376 | -626,784 | -2,479,865 | -1,936,728 | -1,414,390 |
Dividend Paid | -2,180,971 | -2,179,784 | -1,730,241 | -1,725,384 | -1,702,068 |
Other Financing Activity | 0 | 386,137 | 0 | 0 | 0 |
Financing Cash Flow | $-3,438,347 | $-2,420,431 | $-4,210,106 | $-3,662,112 | $-3,116,458 |
Exchange Rate Effect | 8,822 | 2,572 | -12,467 | 1,243 | -1,927 |
Beginning Cash Position | 1,932,289 | 1,931,238 | 1,968,539 | 1,963,013 | 1,936,486 |
End Cash Position | 844,561 | 337,273 | 1,872,365 | 1,555,421 | 1,288,421 |
Net Cash Flow | $-1,087,728 | $-1,593,965 | $-96,174 | $-407,592 | $-648,065 |
Free Cash Flow | |||||
Operating Cash Flow | 2,241,257 | 747,475 | 4,620,270 | 3,653,232 | 2,514,646 |
Capital Expenditure | -278,089 | -128,039 | -576,688 | -440,093 | -274,363 |
Free Cash Flow | 1,963,168 | 619,436 | 4,043,582 | 3,213,139 | 2,240,283 |